Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Abbvie 4Q Results | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Abbvie 4Q Results

Skyrizi and Rinvoq drive growth, offsetting 49% drop in Humira sales.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Image: Abbvie

AbbVie

4Q Revenues: $15.1 billion (+6%)

4Q Loss: $22 million (earnings were $822 million 4Q23)

FY Revenues: $56.3 billion (+4%)

FY Earnings: $4.3 billion (-12%)

Comments: Global immunology portfolio sales in the quarter were $7.3 billion, up 5%. Humira sales were $1.7 billion, down 49%. Skyrizi sales were $3.8 billion, up 58% and Rinvoq sales were $1.8 billion, up 46%.

Global oncology portfolio sales were $1.7 billion, up 12%. Imbruvica sales were $848 million, down 6%. Venclexta sales were $655 million, up 11%. Elahere revenues were $148 million.
 

Global sales from the neuroscience portfolio were $2.5 billion, up 20%. Botox Therapeutic sales were $873 million, up 12.5%. Vraylar sales were $924 million, up 17%. Ubrelvy sales were $303 million, up 30%. Qulipta sales were $201 million, up 76%.

Global revenues from the aesthetics portfolio were $1.3 billion, down 5%. Botox Cosmetic sales were $687 million, down 4%. Juvederm sales were $279 million, down 16%.

Results in the quarter include a charge of $3.5 billion related to the emraclidine intangible asset acquired as part of the Cerevel Therapeutics acquisition and an acquired IPR&D and milestones expense of $1.6 billion.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics